Short Interest in Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Decreases By 35.0%

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) was the recipient of a significant drop in short interest in the month of December. As of December 31st, there was short interest totaling 17,840 shares, a drop of 35.0% from the December 15th total of 27,450 shares. Based on an average daily trading volume, of 25,515 shares, the short-interest ratio is currently 0.7 days. Approximately 0.0% of the shares of the company are sold short. Approximately 0.0% of the shares of the company are sold short. Based on an average daily trading volume, of 25,515 shares, the short-interest ratio is currently 0.7 days.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on PHAR shares. Wall Street Zen raised shares of Pharming Group to a “strong-buy” rating in a report on Saturday, December 27th. Zacks Research lowered shares of Pharming Group from a “strong-buy” rating to a “hold” rating in a research note on Thursday, January 1st. Finally, Weiss Ratings restated a “hold (c-)” rating on shares of Pharming Group in a research report on Monday, December 22nd. Two analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $38.00.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Pharming Group stock. EverSource Wealth Advisors LLC acquired a new stake in shares of Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 2,979 shares of the company’s stock, valued at approximately $32,000. Institutional investors and hedge funds own 0.03% of the company’s stock.

Pharming Group Stock Performance

Shares of PHAR traded up $0.28 during trading hours on Friday, reaching $18.44. 17,891 shares of the company’s stock traded hands, compared to its average volume of 24,799. Pharming Group has a twelve month low of $7.50 and a twelve month high of $19.05. The business’s fifty day simple moving average is $17.18 and its two-hundred day simple moving average is $14.41. The company has a debt-to-equity ratio of 0.35, a current ratio of 3.16 and a quick ratio of 2.39. The firm has a market capitalization of $1.26 billion and a price-to-earnings ratio of -1,842.16.

Pharming Group (NASDAQ:PHAR) last posted its quarterly earnings data on Thursday, November 6th. The company reported $0.10 earnings per share for the quarter, topping the consensus estimate of $0.05 by $0.05. The business had revenue of $97.30 million during the quarter, compared to the consensus estimate of $98.22 million. Pharming Group had a net margin of 0.30% and a return on equity of 0.46%. Analysts predict that Pharming Group will post -0.2 earnings per share for the current year.

Pharming Group Company Profile

Pharming Group N.V. is a clinical-stage biopharmaceutical company headquartered in Leiden, the Netherlands, with a primary focus on developing and commercializing innovative protein replacement therapies for patients living with rare diseases. The company employs a proprietary transgenic technology platform designed to produce recombinant human proteins in the milk of transgenic animals, enabling scalable and cost-efficient manufacturing of complex therapeutic proteins.

The company’s lead product, RUCONEST (recombinant human C1 esterase inhibitor), is approved for the treatment of acute hereditary angioedema (HAE) attacks in multiple markets, including the United States and Europe.